Biogen
BIIB
222.15
-0.74
-0.33%
Biogen
US · BIIB
#623 by market cap
Listed 1970
222.15
-0.74
-0.33%
Live - 5344 symbols - heartbeat 553s ago
· 2026-10-08 04:46
Pre-market
222.80
+0.29%
After-hours
222.15
0.00%
Overnight
221.74
-0.18%
- Market cap
- 32.82B
- P/E (TTM)i
- 39.46
- P/Bi
- 1.74
- EPSi
- 8.79
- Div yieldi
- 0.00%
- 52W posi
- 91%
Reader sentiment
Are you bullish or bearish on BIIB?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 10 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.1 percentage points.
Institutional ownership
- Held by institutions
- 97.47% -0.10pp
- Institutions
- 1,276 -10
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund83.51%
Hedge Fund4.01%
Public Company3.52%
Government Pension Fund2.95%
Sovereign Wealth Fund1.80%
Private Company0.83%
VC/PE Fund0.25%
Individual/Insider0.21%
Insurance Company0.21%
Other2.74%
Top holders as of 2026-06-30
FMR
11.26% · 16.63M sh
BlackRock
10.82% · 15.99M sh
PRIMECAP Management Company
10.26% · 15.15M sh
Vanguard Capital Management, LLC
7.09% · 10.48M sh
State Street Global Advisors
4.97% · 7.34M sh
Vanguard Portfolio Management, LLC
4.47% · 6.60M sh
Geode Capital Management, LLC
3.01% · 4.45M sh
Wellington Management Group
2.11% · 3.12M sh
Norges Bank Investment Management
1.75% · 2.58M sh
UBS Asset Management
1.55% · 2.29M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 35 buys · 15 sells
| Name | Role | Stake |
|---|---|---|
| Susan Alexander | Chief Legal Officer | 0.04% |
| Christopher Viehbacher | Chief Executive Officer | 0.02% |
| Caroline Dorsa | Independent Chairperson | 0.02% |
| Michael McDonnell | Chief Financial Officer | 0.02% |
| Eric Rowinsky | Independent Director | 0.02% |
| Ginger Gregory | Executive Vice President | 0.02% |
| Nicole Murphy | Head of Pharmaceutical Operations & Technology | 0.01% |
| Stephen A. Sherwin | Independent Director | 0.01% |
| Robin Kramer | Chief Accounting Officer | 0.01% |
| Rachid Izzar | Head of Global Product Strategy & Commercialization | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-01 | Sean Godbout | Chief Accounting Officer & Global Corporate Controller | Derivative Exercise and Sale | -8 | $219.88 |
| 2026-10-01 | Sean Godbout | Chief Accounting Officer & Global Corporate Controller | Derivative Exercise and Retained | +19 | -- |
| 2026-09-30 | Sean Godbout | Chief Accounting Officer & Global Corporate Controller | Other Derivative Acquisition | +985 | -- |
| 2026-08-31 | Michael Parini | Chief Legal Officer | Other Derivative Acquisition | +7,405 | -- |
| 2026-08-03 | Lloyd Minor | Directors | Open Market Disposition | -1,186 | $200.96–203.34 |
| 2026-08-03 | Lloyd Minor | Directors | Intent to Sell (Form 144) | -593 | $200.96 |
| 2026-08-02 | Lloyd Minor | Directors | Intent to Sell (Form 144) | -593 | $203.34 |
| 2026-06-08 | Stephen A. Sherwin | Independent Director | Other Acquisition | +1,505 | -- |
| 2026-06-08 | William Hawkins | Independent Director | Other Acquisition | +1,505 | -- |
| 2026-06-08 | Eric Rowinsky | Independent Director | Other Acquisition | +1,505 | -- |
| 2026-06-08 | Maria Freire | Independent Director | Other Acquisition | +2,005 | -- |
| 2026-06-08 | Lloyd Minor | Directors | Other Acquisition | +1,505 | -- |
| 2026-06-08 | Monish Patolawala | Director | Other Acquisition | +1,505 | -- |
| 2026-06-08 | Menelas Nicolas Pangalos | Director | Other Acquisition | +1,505 | -- |
| 2026-06-08 | Menelas Nicolas Pangalos | Director | Derivative Exercise and Retained | +2,370 | -- |
| 2026-06-08 | Jesus Mantas | Independent Director | Other Acquisition | +1,505 | -- |
| 2026-06-08 | Susan Langer | Director | Other Acquisition | +1,505 | -- |
| 2026-04-30 | Adam Keeney | Executive VP & Head of Corporate Development | Derivative Exercise and Sale | -455 | $187.06 |
| 2026-04-30 | Adam Keeney | Executive VP & Head of Corporate Development | Derivative Exercise and Retained | +484 | -- |
| 2026-03-31 | Sean Godbout | Chief Accounting Officer & Global Corporate Controller | Derivative Exercise and Sale | -54 | $183.78 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 04:46:37 · For reference only, not investment advice and not tailored to your situation.